Role of debulking surgery in combination with immune therapy: A successfully treated case of locally advanced mucosal melanoma.
combination therapy
debulking surgery
immune checkpoint inhibitor
mucosal melanoma
nivolumab
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
21
12
2020
accepted:
23
08
2021
entrez:
26
11
2021
pubmed:
27
11
2021
medline:
27
11
2021
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have markedly changed the treatment landscape for melanoma; however, their efficacy and applications are currently limited and medical requirements remain unmet. The present case study reports on a 85-year-old female patient who visited our outpatient clinic with a 1-month history of a buccal mucosa mass and was diagnosed with locally advanced mucosal melanoma of the head and neck. The patient's tumor progressed right after the administration of nivolumab, compromising oral intake. Palliative debulking surgery was performed. Subsequently, the other part of the melanoma on the hard palate slightly decreased in size without forming new lesions for more than one year after surgery. The present case exemplifies that tumor volume reduction surgery may increase the response to ICI and may prolong the duration of response. This combination therapy may be more effective in patients whose tumors increase in size after administration of ICIs or whose tumor is already large at the beginning of treatment. The combination of ICIs and debulking surgery may become an important treatment option in the future for locally advanced mucosal melanoma.
Identifiants
pubmed: 34824842
doi: 10.3892/mco.2021.2435
pii: MCO-16-1-02435
pmc: PMC8609515
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2Informations de copyright
Copyright © 2020, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
BMC Cancer. 2017 Nov 21;17(1):778
pubmed: 29162045
J Investig Med High Impact Case Rep. 2018 Jul 06;6:2324709618786319
pubmed: 30083560
Hematol Oncol Clin North Am. 2009 Jun;23(3):383-95, vii
pubmed: 19464592
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Head Neck. 2016 Jan;38(1):147-55
pubmed: 25242350
J Clin Oncol. 2017 Jan 10;35(2):226-235
pubmed: 28056206
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
J Hematol Oncol. 2018 Aug 16;11(1):104
pubmed: 30115069
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Sci Rep. 2019 Nov 15;9(1):16902
pubmed: 31729430
Nature. 2007 Feb 22;445(7130):851-7
pubmed: 17314971
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551